Pharvaris N.V. (PHVS) Stock Price, Quote & News

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 tria...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 712036410

Website: pharvaris.com

Address:

Grafenauweg 8, Zug, Switzerland

TheHiddenMass Dec. 24 at 12:06 PM

$PHVS Current positioning will be tested as timelines compress uncertainty rather than extend speculation. Delays or dilution could materially reshape the risk profile.

0 · Reply

Arcides Dec. 10 at 5:40 PM

$PHVS total disgrace after big pop 6 days ago.

0 · Reply

Quantumup Dec. 4 at 6:35 PM

Morgan Stanley⬆️ $PHVS' PT to $41 from $37 and reiterated at Overweight $KALV Oppenheimer⬆️to $50 from $44 and reit'd at Outperform Guggenheim⬆️to $39 from $32, +⬆️its🌐peak sales ests for deucrictibant to $1.65B from $1.4B Here's what the Analysts said in their notes: https://x.com/Quantumup1/status/1996647560816087150?s=20

0 · Reply

ZacksResearch Dec. 4 at 6:11 PM

PHVS ripping higher — is this the momentum shift bulls wanted? Deucrictibant hit its late-stage marks with rapid symptom relief in RAPIDe-3, and the win is pushing $PHVS toward a planned 2026 regulatory filing. Full breakdown here 👉 https://www.zacks.com/stock/news/2799891/pharvaris-stock-gains-on-hae-drug-meeting-late-stage-study-goals?cid=sm-stocktwits-2-2799891-teaser-23504&ADID=SYND_STOCKTWITS_TWEET_2_2799891_TEASER_23504

0 · Reply

JarvisFlow Dec. 4 at 6:10 PM

Oppenheimer has updated their rating for Pharvaris ( $PHVS ) to Outperform with a price target of 50.

0 · Reply

ZacksResearch Dec. 4 at 5:11 PM

$PHVS skyrockets 22% on positive phase III results for HAE drug! 🚀 🎯 Deucrictibant achieved its primary endpoint and all secondary endpoints in RAPIDe-3 study, offering faster relief than placebo. 💊 83% of attacks managed with one dose; 93% without backup treatment. Find out what this means for Pharvaris and its competition with $KALV 👉 https://www.zacks.com/stock/news/2799891/pharvaris-stock-gains-on-hae-drug-meeting-late-stage-study-goals?cid=sm-stocktwits-2-2799891-body-23505&ADID=SYND_STOCKTWITS_TWEET_2_2799891_BODY_23505

0 · Reply

TwongStocks Dec. 4 at 3:29 PM

$PHVS They currently have 3 USPTO trademark applications for the following names: • HAEBRII, application filed June 30, 2025 • ATASFRII, application filed Mar 26, 2025 • BRADIFRII, application filed Mar 26, 2025 Unless they process additional applications, I assume one of these names will be the marketing name for deucrictibant.

0 · Reply

FireIn Dec. 4 at 3:27 PM

$PHVS RAPIDe-3 pivotal Phase 3 hit primary + all 11 secondary endpoints (p<0.0001).Fast onset (symptom relief 1.28h), early complete resolution (11.95h), strong safety. Data will support global filings starting 1H26. Deucrictibant building a legit case as best-in-class oral on-demand HAE therapy.

0 · Reply

JarvisFlow Dec. 4 at 1:55 PM

Guggenheim updates rating for Pharvaris ( $PHVS ) to Buy, target set at 32 → 39.

0 · Reply

JarvisFlow Dec. 4 at 1:04 PM

Morgan Stanley has adjusted their stance on Pharvaris ( $PHVS ), setting the rating to Overweight with a target price of 37 → 41.

0 · Reply

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Dec 3, 2025, 10:09 AM EST - 21 days ago

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Dec 3, 2025, 6:50 AM EST - 21 days ago

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Nov 23, 2025, 5:36 AM EST - 4 weeks ago

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Nov 12, 2025, 6:50 AM EST - 6 weeks ago

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 6:50 AM EST - 6 weeks ago

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Oct 23, 2025, 6:50 AM EDT - 2 months ago

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Sep 10, 2025, 1:07 PM EDT - 3 months ago

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 1:04 AM EDT - 3 months ago

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 5:25 AM EDT - 3 months ago

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 3:15 PM EDT - 5 months ago

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Jul 22, 2025, 9:22 PM EDT - 5 months ago

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Jul 22, 2025, 4:05 PM EDT - 5 months ago

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Jul 18, 2025, 4:41 AM EDT - 5 months ago

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Jul 10, 2025, 6:50 AM EDT - 5 months ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Jun 27, 2025, 6:50 AM EDT - 6 months ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Jun 16, 2025, 6:50 AM EDT - 6 months ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Jun 10, 2025, 6:50 AM EDT - 7 months ago

Pharvaris Announces Annual Meeting of Shareholders

Jun 2, 2025, 6:50 AM EDT - 7 months ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

May 19, 2025, 6:50 AM EDT - 7 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

May 13, 2025, 4:05 PM EDT - 8 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 6:50 AM EDT - 8 months ago

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Apr 7, 2025, 6:58 AM EDT - 9 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 1, 2025, 6:50 AM EDT - 9 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Mar 3, 2025, 6:50 AM EST - 10 months ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Mar 3, 2025, 6:48 AM EST - 10 months ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Jan 13, 2025, 6:50 AM EST - 1 year ago

Pharvaris Outlines 2025 Strategic Priorities

Nov 13, 2024, 4:10 PM EST - 1 year ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 12, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Oct 16, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Oct 15, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Oct 3, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Sep 5, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024, 6:49 AM EDT - 1 year ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Sep 5, 2024, 6:48 AM EDT - 1 year ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Aug 28, 2024, 6:50 AM EDT - 1 year ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

May 13, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 8, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 10, 2024, 4:08 PM EDT - 1 year ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Apr 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Mar 18, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Mar 6, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Mar 5, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Feb 22, 2024, 6:50 AM EST - 1 year ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Feb 16, 2024, 6:50 AM EST - 2 years ago

Pharvaris Announces Extraordinary Meeting of Shareholders

Jan 26, 2024, 6:50 AM EST - 2 years ago

Pharvaris to Present at the WSAAI Annual Meeting 2024

TheHiddenMass Dec. 24 at 12:06 PM

$PHVS Current positioning will be tested as timelines compress uncertainty rather than extend speculation. Delays or dilution could materially reshape the risk profile.

0 · Reply

Arcides Dec. 10 at 5:40 PM

$PHVS total disgrace after big pop 6 days ago.

0 · Reply

Quantumup Dec. 4 at 6:35 PM

0 · Reply

ZacksResearch Dec. 4 at 6:11 PM

0 · Reply

JarvisFlow Dec. 4 at 6:10 PM

Oppenheimer has updated their rating for Pharvaris ( $PHVS ) to Outperform with a price target of 50.

0 · Reply

ZacksResearch Dec. 4 at 5:11 PM

0 · Reply

TwongStocks Dec. 4 at 3:29 PM

0 · Reply

FireIn Dec. 4 at 3:27 PM

0 · Reply

JarvisFlow Dec. 4 at 1:55 PM

Guggenheim updates rating for Pharvaris ( $PHVS ) to Buy, target set at 32 → 39.

0 · Reply

JarvisFlow Dec. 4 at 1:04 PM

Morgan Stanley has adjusted their stance on Pharvaris ( $PHVS ), setting the rating to Overweight with a target price of 37 → 41.

0 · Reply

JarvisFlow Dec. 4 at 12:14 PM

B of A Securities updates rating for Pharvaris ( $PHVS ) to Neutral, target set at 27 → 30.

0 · Reply

Sambong Dec. 4 at 8:27 AM

$PHVS chart looks amazing

0 · Reply

BearTamerTrading Dec. 4 at 2:30 AM

📈 Market Alerts — Bear Tamer Trading 🔥 $KITT — Robotics/automation name with strong intraday momentum and steady higher-lows reclaim. 🔥 $MCRP — Micro-cap runner showing sharp volatility and heavy liquidity rotations during market hours. 🔥 $AHMA — Recent low-float mover with controlled intraday trend and consistent grind. 🔥 $IRBT — Robotics sector name attracting volume from headline attention + intraday range strength. 🔥 $PHVS — Pharma/biotech name with solid liquidity and clean intraday push structure. Congrats to everyone who caught these live on Market Alerts today 💰👏 Here’s the proof we alerted all of them live ⬇️ 🔗 https://www.youtube.com/live/glMYt0HMYn0?si=7S_Ahf2_zcaXnG2b Stay tuned, the momentum doesn’t stop. 🚀

0 · Reply

WycklyTrader Dec. 3 at 11:10 PM

$PHVS 52wk high (re-accumulation) on positive phase3 data with expected PDUFA catalyst. QNCX 52wk high base breakout momentum with phase3 data due 1Q2026. $IBB $XLV $SPY $QQQ :..

0 · Reply

Sw1ngb0t Dec. 3 at 10:28 PM

$PHVS $CCCC $GOSS $ERAS some newbs

0 · Reply

prismmarketview Dec. 3 at 8:12 PM

Pharvaris (Nasdaq: $PHVS) reported strong Phase 3 data for deucrictibant, showing rapid symptom relief and a clean safety profile in HAE attacks. The results support its upcoming 2026 NDA for on-demand treatment. https://prismmarketview.com/pharvaris-reports-strong-phase-3-results-supporting-deucrictibant-for-on-demand-hae-treatment/

0 · Reply

JarvisFlow Dec. 3 at 7:14 PM

HC Wainwright & Co. has adjusted their stance on Pharvaris ( $PHVS ), setting the rating to Buy with a target price of 60.

0 · Reply

Profitrip Dec. 3 at 3:34 PM

$ARWR $SMX $BOX $PHVS on my breakout scan!

0 · Reply

TaxWriteOffsPls Dec. 3 at 3:07 PM

$PHVS Great data, they blow KALV out of the water and this reinforces future extended-release readout. I think it will run up eventually before Chapter-3 which is hopefully going to be a chance to trim position

0 · Reply

JFais Dec. 3 at 2:51 PM

$KALV (L) Verdict on my position post $PHVS phase 3 data (done well in it so far since entry at October lows)

1 · Reply

JFais Dec. 3 at 2:48 PM

Both $KALV & $PHVS up on the latter's idea- an unexpected outcome

0 · Reply

Silky007 Dec. 3 at 2:27 PM

$PHVS 3 minutes

0 · Reply

Market Cap	1.35B
Revenue (ttm)	0.00
Net Income (ttm)	-145.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	57,000
Avg Vol	376,298
Day's Range	N/A - N/A
Shares Out	52.29M
Stochastic %K	60%
Beta	-2.80
Analysts	Strong Sell
Price Target	$44.50